Blood Pressure Meds Point the Way to Possible COVID-19 Treatment

There is little evidence that antihypertensive drugs worsen COVID-19, and scientists are instead exploring the idea that such medications—or their downstream effects—may actually alleviate symptoms.

Written byAshley Yeager

| 7 min read

Save for Later

Listen with Speechify

0:00

7:00

ABOVE: A coronavirus spike protein (red) binds to an ACE2 receptor (blue) in this illustration.
© ISTOCK.COM, SELVANEGRA

For the past few weeks, research journals have been publishing reports on the connection between medications that reduce high blood pressure and COVID-19. The concern is that the medications might increase the abundance of the receptor that SARS-CoV-2—the virus that causes COVID-19—uses to enter cells. Boosting levels of these ACE2 receptors on lung and heart cells could give the virus more cellular entry points to target and potentially make symptoms of the disease more severe.

It’s a hypothesis that is important to test, notes Carlos Ferrario, a professor of general surgery at Wake Forest School of Medicine who specializes in research on antihypertensive drugs.

So far, the data supporting the connection between blood pressure medications—specifically, angiotensin-converting-enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs)—and COVID-19 are scant. Yet media coverage of the connection has ...

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!

Join for free today

Already a member?

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

Ashley Yeager
Ashley started at The Scientist in 2018. Before joining the staff, she worked as a freelance editor and writer, a writer at the Simons Foundation, and a web producer at Science News, among other positions. She holds a bachelor’s degree in journalism from the University of Tennessee, Knoxville, and a master’s degree in science writing from MIT. Ashley edits the Scientist to Watch and Profile sections of the magazine and writes news, features, and other stories for both online and print.
View Full Profile